Effects of the PPAR-γ Agonist Rosiglitazone on Renal Haemodynamics and the Renin-Angiotensin System in Diabetes

Abstract

Background. Thiazolidinediones (TZD) have been reported to improve early stages of diabetic nephropathy independent of glycaemic control. Since blockade of the renin-angiotensin system (RAS) is known to reduce the risk of nephropathy, we hypothesised that the renal effect of TZDs might be related to a favourable effect on the intrarenal RAS. We aimed to determine if the TZD rosiglitazone could reduce RAS activation.

Methods. We studied adult type 2 diabetic patients and placed them on rosiglitazone for three months. We have previously used the renal haemodynamic response to angiotensin-converting enzyme (ACE) inhibition to demonstrate the state of RAS activation, and thus measured renal plasma flow (RPF) and glomerular filtration rate (GFR) before and after administration of captopril at 0 month and at three months. Plasma renin activity (PRA), active renin, aldosterone and natriuretic peptides were analysed.

Results. The RPF response to ACE inhibition was not altered.There was no change in GFR, PRA, active renin and aldosterone levels. Two patients developed oedema — one had an elevated baseline active renin and another had an elevated baseline aldosterone level.

Conclusion. The favourable effects of TZDs on diabetic nephropathy is likely not related to an influence on the RAS.

Keywords

Diabetes PPAR-gamma Thiazolidinedione Renin-angiotensin system

Get full access to this article

View all access options for this article.

References

Pistrosch F. , Passauer J. , Fischer S. , Fuecker K. , Hanefeld M. , Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of

glucose control. Diabetes Care 2004;27:484-90.

Bloomgarden ZT Thiazolidinediones. Diabetes Care 2005;28:488-93. 3. Phillips LS , Grunberger G. , Miller E. , Patwardhan R. , Rappaport EB , Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-15.

Nakamura T. , Ushiyama C. , Osada S. , Hara M. , Shimada N. , Koide H. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-6.

Nakamura T. , Ushiyama C. , Suzuki S. et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18: 308-13.

Pistrosch F. , Herbrig K. , Kindel B. , Passauer J. , Fischer S. , Gross P. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 2005;54:2206-11.

Bakris G. , Viberti G. , Weston WM , Heise M. , Porter LE , Freed MI Rosiglitazone reduces urinary albumin excretion in type II diabetes . J Hum Hypertens 2003;17:7-12.

Price DA , Fisher ND , Osei SY , Lansang MC , Hollenberg NK Renal perfusion and function in healthy African Americans. Kidney Int 2001;59:1037-43.

Lansang MC , Osei SY , Price DA , Fisher ND , Hollenberg NK Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan. Hypertension 2000;36: 834-8.

10.

Osei SY , Price DA , Laffel LM , Lansang MC , Hollenberg NK Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans. Hypertension 2000;36: 122-6.

11.

De'Oliveira JM , Price DA , Fisher ND et al. Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney Int 1997 ;52:771-7.

12.

Lansang MC , Price DA , Laffel LM et al. Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus. Kidney Int 2001;59:1432-8.

13.

The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl 1):S5-S10.

14.

Tanimoto M. , Fan Q. , Gohda T. , Shike T. , Makita Y. , Tomino Y. Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK/Ta mice. Metabolism 2004;53:1473-9.

15.

Baylis C. , Atzpodien EA , Freshour G. , Engels K. Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 2003;307:854-60.

16.

Harte A. , McTernan P. , Chetty R. et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005;111:1954-61.

17.

Bjorck S. , Delin K. , Herlitz H. , Larsson O. , Aurell M. Renin secretion in advanced diabetic nephropathy. Scand J Urol Nephrol Suppl 1984;79:53-7.

18.

Christlieb AR , Kaldany A. , D'Elia JA Plasma renin activity and hypertension in diabetes mellitus. Diabetes 1976;25:969-74.

19.

Fisher ND , Price DA , Litchfield WR , Williams GH , Hollenberg NK Renal response to captopril reflects state of local renin system in healthy humans. Kidney Int 1999;56:635-41.

20.

Price DA , Porter LE , Gordon M. et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382-91.

21.

Price DA , De'Oliveira JM , Fisher ND , Williams GH , Hollenberg NK The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999;12:348-5

22.

Lansang MC , Stevanovic R. , Price DA , Laffel LM , Hollenberg NK ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus. Kidney Int 2005 ;67:1033-7.

23.

Price DA , Lansang MC , Osei SY , Fisher ND , Laffel LM , Hollenberg NK Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan. Diabet Med 2002;19:858-61.

24.

Zanchi A. , Chiolero A. , Maillard M. , Nussberger J. , Brunner HR , Burnier M. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140-5.

25.

Lewis EJ Angiotensin-converting enzyme inhibitors: considerations regarding proteinuria . Am J Kidney Dis 1987;10(1 Suppl 1):30-8.

26.

Lewis EJ , Hunsicker LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

27.

Brenner BM , Cooper ME , de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.

28.

Parving HH , Lehnert H. , Brochner-Mortensen J. , Gomis R. , Andersen S. , Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2

29.

diabetes. N Engl J Med 2001;345:870-8. 29 Lansang MC , Osei SY , Coletti C. , Krupinski J. , Hollenberg NK Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways. JRAAS 2002;3:19-23.

30.

Lansang MC , Hollenberg NK

Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?

Diabetes 2002;51:2025-8.

31.

Yosefy C. , Magen E. , Kiselevich A. et al. Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004;44:215-22.